Physician profile
Romona Devi Satchi
NPI 1295025096
$1,805.79
in general payments reported to CMS, 2019-2025
26 companies · $532 in 2025
The $532 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,051 · 2020: $222 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $516 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $516.11 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $304.87 | 2019-2025 | Ozempic |
| Lilly USA, LLC | $272.71 | 2019-2020 | |
| Medtronic, INC. | $189.63 | 2025 | Minimed 780g |
| Amgen INC. | $148.04 | 2019-2025 | Tepezza |
| Abbvie INC. | $132.53 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.51 | 2019-2020 | |
| Insulet Corporation | $80.37 | 2019-2025 | Omnipod |
| Sunovion Pharmaceuticals INC. | $61.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $61.59 | 2019-2020 | |
| Ibsa Pharma INC. | $47.00 | 2025 | Tirosint, Flector, Licart |
| Abbott Laboratories | $41.86 | 2019 | |
| Sanofi-Aventis U.S. LLC | $40.00 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $34.18 | 2019 | |
| Sequel Med Tech, LLC | $32.97 | 2025 | Twiist |
| Glaxosmithkline, LLC. | $32.64 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $31.11 | 2019 | |
| Ascendis Pharma Endocrinology INC | $29.78 | 2025 | Yorvipath |
| Amarin Pharma, INC. | $28.41 | 2019-2020 | |
| Shire North American Group INC | $20.88 | 2019 | |
| Scilex Pharmaceuticals INC. | $19.02 | 2019 | |
| Mannkind Corporation | $17.32 | 2025 | |
| Vanda Pharmaceuticals INC. | $16.29 | 2019 | |
| Horizon Therapeutics Plc | $15.50 | 2019 | |
| Tandem Diabetes Care, INC. | $14.84 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Hikma Pharmaceuticals USA | $13.10 | 2019 | |
| Senseonics, Incorporated | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Romona Satchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.